APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration

Michael N. Cohen; Denis O’Shaughnessy; Kate Fisher; Jennifer Cerami; Carl C Awh; Daniel E Salazar; Philip Rosenfeld; Jeffrey S Heier

doi:10.1136/bjophthalmol-2020-316511

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via AAO

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Browse by collection

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via AAO

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Clinical science

APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Cohen MN, O’Shaughnessy D, Fisher K, et al

APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration

British Journal of Ophthalmology 2021;105:716-722.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password